建了水泡性口炎病毒的M基因的第51位氨基酸缺失和第221位和226位氨基酸进行了突变的重 组水泡性口炎病毒(VSV△MT),为后面的该病毒在本体动物上有效性和安全性研究提供了 基础和前提。 参考文献 [1].Rose JK,Whitt MA.Rhabdoviridae:the viruses and their replication.In:Knipe DM,Howley PM editors.Fields Virology,vol.1 Philadelphia:Lipopincot willianms &Wilkins,2001, p.1221-1244. [2]Bridges VE,McCluskey BJ,Salman MD,et al.Review of the 1995 vesicular stomatitis outbreak in the western United States[J].J Am Vet Med Assoc.1997,211(5):556-60. [3]Martinez I,Barrera JC,Rodriguez LL,et al.Recombinant vesicular stomatitis(Indiana)virus expressing New Jersey and Indiana glycoproteins induces neutralizing antibodies to each serotype in swine,a natural host.Vaccine 2004:22(29-30):4035-43. [4]Schnell MJ,Buonocore L,Kretzschmar E,et al.Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles.Proc Natl Acad Sci USA1996:9321):11359-65. []孙洪正，徐自忠，周晓黎，等.水疱性口炎研究进展[J].动物医学进展，2007,28(10)： 72-76. [6]Chong L D,Rose J K.Membrane association of functional vesicular stomatitis virus matrix protein in vivo[J].J Virol,1993,67(1):407~414. [7]Hoffmann M,Wu Y J,Gerber M,et al.Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity[J].J Gen Virol,2010,9(11): 2782~2793 [8]Kopecky S A,Lyles D S.The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death[J].JVirol,2003,77(9):5524~5528. [9]Bi Z,Barna M,Komatsu T,Reiss CS.Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity.J Viro/1995;69(10):6466-72. [10]Johnson JE,Nasar F,Coleman JW,et al.Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates.Virology 2007;360(1):36-49. [11]STOJDL DF,LICHTY BD,TENOEVER BR,et al.VSV strains whith defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents[j].Cancer Cell,2003, 4(4):263-275. [12]Lawson ND,Stillman EA,Whitt MA,et al.Recombinant vesicular stomatitis viruses from DNA[J].Proc Natl Acad Sci USA.1995,92(10):4477-81. [13]Sambrook J,Russel1D".分子克隆实验指南[M].黄培堂等.3版.北京：科学出版社， 2008:1034. [14]HUANG TG,SAVONTAUS MJ,SHINOZAKI K,et al.Telomerase-dependnt oncolytic adenovirus for cancer treatment[J].Gene Ther,2003,10(15):1241-1247. [15]GARBUTT M,LIEBSCHER R,WAHL-JENSEN V,et al.Properties of replication -competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses[J].J Virol,2004,78(10):5458-5465. [16]KELLY E J,HADAC E M,GREINER S,et al.Engineering microRNA responsiveness to decrease virus pathogenicity[J].Nat Med,2008,14(11):1278-1283.建了水泡性口炎病毒的M基因的第51位氨基酸缺失和第221位和226位氨基酸进行了突变的重 组水泡性口炎病毒（VSVΔMT），为后面的该病毒在本体动物上有效性和安全性研究提供了 基础和前提。 参考文献 [1].Rose JK, Whitt MA. Rhabdoviridae: the viruses and their replication. In: Knipe DM, Howley PM editors. Fields Virology, vol.1 Philadelphia: Lipopincot willianms &Wilkins, 2001, p.1221-1244. [2] Bridges VE, McCluskey BJ, Salman MD, et al. Review of the 1995 vesicular stomatitis outbreak in the western United States[J]. J Am Vet Med Assoc. 1997, 211(5):556-60. [3]Martinez I, Barrera JC, Rodriguez LL, et al. Recombinant vesicular stomatitis (Indiana) virus expressing New Jersey and Indiana glycoproteins induces neutralizing antibodies to each serotype in swine, a natural host. Vaccine 2004;22(29-30):4035–43. [4]Schnell MJ, Buonocore L, Kretzschmar E, et al. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A 1996;93(21): 11359–65. [5]孙洪正，徐自忠，周晓黎，等. 水疱性口炎研究进展[J]. 动物医学进展， 2007，28(10)： 72~76. [6]Chong L D, Rose J K.Membrane association of functional vesicular stomatitis virus matrix protein in vivo[J]. J Virol, 1993, 67(1):407~414. [7]Hoffmann M, Wu Y J, Gerber M, et al.Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity[J]. J Gen Virol, 2010, 9(11): 2782~2793. [8]Kopecky S A, Lyles D S. The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death[J]. J Virol, 2003, 77(9): 5524~5528. [9] Bi Z, Barna M, Komatsu T, Reiss CS. Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J Virol 1995;69(10):6466–72. [10] Johnson JE, Nasar F, Coleman JW, et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 2007;360(1):36–49. [11]STOJDL DF,LICHTY BD,TENOEVER BR,et al. VSV strains whith defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents[j].Cancer Cell, 2003, 4(4) :263-275. [12] Lawson ND, Stillman EA, Whitt MA, et al. Recombinant vesicular stomatitis viruses from DNA[J]. Proc Natl Acad Sci USA. 1995, 92(10):4477–81. [13]Sambrook J，Russell D W.分子克隆实验指南[M]．黄培堂等．3版．北京：科学出版社， 2008：1034. [14]HUANG TG, SAVONTAUS MJ, SHINOZAKI K, et al. Telomerase-dependnt oncolytic adenovirus for cancer treatment[J]. Gene Ther, 2003,10(15):1241-1247. [15]GARBUTT M, LIEBSCHER R, WAHL-JENSEN V, et al. Properties of replication –competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses[J]. J Virol, 2004,78(10):5458-5465. [16]KELLY E J, HADAC E M, GREINER S, et al. Engineering microRNA responsiveness to decrease virus pathogenicity[J]. Nat Med, 2008, 14(11):1278-1283